Výsledky vyhledávání - Vincent A. Miller

Upřesnit hledání
  1. 1
    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer Autor Jennifer Clarke, William Pao, Nian Wu, Vincent A. Miller, Andrew B. Lassman

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Autor Geoffrey R. Oxnard, Maria E. Arcila, Juliann Chmielecki, Marc Ladanyi, Vincent A. Miller, William Pao

    Vydáno 2011
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Cl... Autor Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, Gregory J. Riely

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma Autor James Bean, Gregory J. Riely, Marissa N. Balak, Jenifer L. Marks, Marc Ladanyi, Vincent A. Miller, William Pao

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling Autor Angel Qin, Adrienne Johnson, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock, Shirish M. Gadgeel

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping Autor Geoffrey R. Oxnard, Vincent A. Miller, Mark E. Robson, Christopher G. Azzoli, William Pao, Marc Ladanyi, Maria E. Arcila

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden Autor Victoria E. Wang, Anatoly Urisman, Lee A. Albacker, Siraj M. Ali, Vincent A. Miller, Rahul Aggarwal, David M. Jablons

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities Autor Sherri Z. Millis, Denis L. Jardim, Lee A. Albacker, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Razelle Kurzrock

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain Autor William Pao, Vincent A. Miller, Katerina Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, Mark G. Kris, Harold Varmus

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations

    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations Autor Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study

    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study Autor Vineeta Agarwala, Sean Khozin, Gaurav Singal, Claire O’Connell, Deborah Kuk, Gerald Li, Anala Gossai, Vincent A. Miller, Amy P. Abernethy

    Vydáno 2018
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors Autor Darren Sigal, Munveer S. Bhangoo, Jonathan A. Hermel, Dean C. Pavlick, Garrett M. Frampton, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation Autor Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    EGFR Mutations in Lung Adenocarcinomas

    EGFR Mutations in Lung Adenocarcinomas Autor Allan R. Li, Dhananjay Chitale, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski, Valerie W. Rusch, Mark G. Kris, Marc Ladanyi

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib Autor Melissa L. Johnson, Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, Vincent A. Miller

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers Autor Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip Pravin Patel, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies Autor Aaron M. Goodman, Shumei Kato, Philip R. Cohen, Amélie Boichard, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer Autor Vincent A. Miller, James R. Rigas, Prudence A. Francis, Stefan C. Grant, Katherine M.W. Pisters, Mark G. Kris, Karen Woolley, Ennapadam Venkatraman, Robert T. Heelan

    Vydáno 1995
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Autor William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, Maureen F. Zakowski, Robert T. Heelan, Mark G. Kris, Harold Varmus

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors Autor Jennifer J. Wheler, Johnique T. Atkins, Filip Janků, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda Meric‐Bernstam

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: